Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition

Benjamin, 2011, Rapamycin passes the torch: a new generation of mTOR inhibitors, Nat. Rev. Drug Discov., 10, 868, 10.1038/nrd3531

Choo, 2008, Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation, Proc. Natl. Acad. Sci. USA, 105, 17414, 10.1073/pnas.0809136105

Dibble, 2013, Signal integration by mTORC1 coordinates nutrient input with biosynthetic output, Nat. Cell Biol., 15, 555, 10.1038/ncb2763

Dibble, 2009, Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1, Mol. Cell. Biol., 29, 5657, 10.1128/MCB.00735-09

Ducker, 2014, Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors, Oncogene, 33, 1590, 10.1038/onc.2013.92

Eke, 2015, Focal adhesion signaling and therapy resistance in cancer, Semin. Cancer Biol., 31, 65, 10.1016/j.semcancer.2014.07.009

Feldman, 2009, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol., 7, e38, 10.1371/journal.pbio.1000038

Fernandez, 2009, Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation, J. Immunol., 182, 2063, 10.4049/jimmunol.0803600

Fruman, 2014, PI3K and cancer: lessons, challenges and opportunities, Nat. Rev. Drug Discov., 13, 140, 10.1038/nrd4204

García-Martínez, 2008, mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1), Biochem. J., 416, 375, 10.1042/BJ20081668

García-Martínez, 2009, Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR), Biochem. J., 421, 29, 10.1042/BJ20090489

Giraud, 2001, Translation initiation of the insulin-like growth factor I receptor mRNA is mediated by an internal ribosome entry site, J. Biol. Chem., 276, 5668, 10.1074/jbc.M005928200

Gulhati, 2011, mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways, Cancer Res., 71, 3246, 10.1158/0008-5472.CAN-10-4058

Hannigan, 2005, Integrin-linked kinase: a cancer therapeutic target unique among its ILK, Nat. Rev. Cancer, 5, 51, 10.1038/nrc1524

Hennig, 2006, TOR coordinates bulk and targeted endocytosis in the Drosophila melanogaster fat body to regulate cell growth, J. Cell Biol., 173, 963, 10.1083/jcb.200511140

Hsieh, 2012, The translational landscape of mTOR signalling steers cancer initiation and metastasis, Nature, 485, 55, 10.1038/nature10912

Hsu, 2011, The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling, Science, 332, 1317, 10.1126/science.1199498

Hu, 2013, Integrin bi-directional signaling across the plasma membrane, J. Cell. Physiol., 228, 306, 10.1002/jcp.24154

Komar, 2011, Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states, Cell Cycle, 10, 229, 10.4161/cc.10.2.14472

Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017

Legate, 2009, Genetic and cell biological analysis of integrin outside-in signaling, Genes Dev., 23, 397, 10.1101/gad.1758709

Li, 2014, Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells, J. Exp. Med., 211, 15, 10.1084/jem.20131080

Li, 2014, Rapamycin: one drug, many effects, Cell Metab., 19, 373, 10.1016/j.cmet.2014.01.001

Liu, 2010, Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer, J. Med. Chem., 53, 7146, 10.1021/jm101144f

Liu, 2013, Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis, Nat. Cell Biol., 15, 1340, 10.1038/ncb2860

Ma, 2011, Development of focal adhesion kinase inhibitors in cancer therapy, Anticancer. Agents Med. Chem., 11, 638, 10.2174/187152011796817628

Ma, 2009, Molecular mechanisms of mTOR-mediated translational control, Nat. Rev. Mol. Cell Biol., 10, 307, 10.1038/nrm2672

Mahajan, 2012, PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics, J. Cell. Physiol., 227, 3178, 10.1002/jcp.24065

Manning, 2007, AKT/PKB signaling: navigating downstream, Cell, 129, 1261, 10.1016/j.cell.2007.06.009

Muranen, 2012, Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells, Cancer Cell, 21, 227, 10.1016/j.ccr.2011.12.024

Olson, 2013, The insulin receptor cellular IRES confers resistance to eIF4A inhibition, eLife, 2, e00542, 10.7554/eLife.00542

Rodrik-Outmezguine, 2011, mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling, Cancer Discov., 1, 248, 10.1158/2159-8290.CD-11-0085

Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148

Seguin, 2015, Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance, Trends Cell Biol., 25, 234, 10.1016/j.tcb.2014.12.006

Silvera, 2010, Translational control in cancer, Nat. Rev. Cancer, 10, 254, 10.1038/nrc2824

Su, 2011, Mammalian TOR signaling to the AGC kinases, Crit. Rev. Biochem. Mol. Biol., 46, 527, 10.3109/10409238.2011.618113

Sykes, 2011, AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias, Cell, 146, 697, 10.1016/j.cell.2011.07.032

Thomson, 2009, Immunoregulatory functions of mTOR inhibition, Nat. Rev. Immunol., 9, 324, 10.1038/nri2546

Thoreen, 2009, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1, J. Biol. Chem., 284, 8023, 10.1074/jbc.M900301200

Thoreen, 2012, A unifying model for mTORC1-mediated regulation of mRNA translation, Nature, 485, 109, 10.1038/nature11083

Thorpe, 2015, PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting, Nat. Rev. Cancer, 15, 7, 10.1038/nrc3860

Um, 2004, Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity, Nature, 431, 200, 10.1038/nature02866

Vadlakonda, 2013, The paradox of Akt-mTOR interactions, Front. Oncol., 3, 165, 10.3389/fonc.2013.00165

Yu, 2011, Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling, Science, 332, 1322, 10.1126/science.1199484

Zhang, 2012, mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors, Cell Cycle, 11, 594, 10.4161/cc.11.3.19096

Zhao, 2015, mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy, Proc. Natl. Acad. Sci. USA, 112, 15790, 10.1073/pnas.1521919112

Zhou, 2011, Role of mTOR signaling in tumor cell motility, invasion and metastasis, Curr. Protein Pept. Sci., 12, 30, 10.2174/138920311795659407